⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Camelx and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Camelx
↗Riyadh, Saudi Arabia
Camelx is a Saudi Arabian biotechnology company focused on pioneering biomedical innovation by harnessing the unique biology of camels. The company aims to develop novel biologic therapies derived from indigenous resources to address unmet medical needs and support Saudi Arabia's Vision 2030 and National Biotechnology Strategy.
Founded in 2025, the company operates as a boutique R&D firm, emphasizing ethical research and sustainable practices. Camelx is actively building an innovation ecosystem that includes strategic partnerships with global pharmaceutical entities to commercialize camel-derived therapeutics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$5M
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Global pharmaceutical company (signed March 2025 for co-development and commercialization)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Shaima Hamidaddin - Co-founder & CEO
Dr. Mohamed Ali Diriye - Co-founder & Chief Medical Officer
Dr. Eltayeb Eid - Co-founder & Chief Science Officer
Scientific Founders:Shaima Hamidaddin, Dr. Mohamed Ali Diriye, Dr. Eltayeb Eid
LINKS
Website:camelx.sa
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Camelx. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.